The Economic Times daily newspaper is available online now.

    Buy Syngene International, target price Rs 660: Yes Securities

    Synopsis

    Syngene International Ltd., incorporated in the year 1993, is a Mid Cap company (having a market cap of Rs 24969.62 Crore) operating in Pharmaceuticals sector.

    BuyThinkStock Photos
    Promoters held 70.42 per cent stake in the company as of 30-Sep-2021, while FIIs owned 14.23 per cent, DIIs 4.66 per cent.
    Yes Securities has buy call on Syngene International with a target price of Rs 660. The current market price of Syngene International is Rs 622.6.

    Time period given by analyst is Intra Day when Syngene International Ltd. price can reach defined target.
    Syngene International Ltd., incorporated in the year 1993, is a Mid Cap company (having a market cap of Rs 24969.62 Crore) operating in Pharmaceuticals sector.

    Syngene International Ltd. key Products/Revenue Segments include Contract Research & Contract Manufacturing (CRAMS), Other Operating Revenue, Export Incentives and Scrap for the year ending 31-Mar-2021.


    Financials
    For the quarter ended 30-09-2021, the company reported a Consolidated Total Income of Rs 623.10 Crore, up 2.69 % from last quarter Total Income of Rs 606.80 Crore and up 16.82 % from last year same quarter Total Income of Rs 533.40 Crore. Company reported net profit after tax of Rs 66.70 Crore in latest quarter.

    Investment Rationale
    The appearance of a large bullish candle and swift reversal from the lower levels in the recent past suggests a resumption of uptrend

    Promoter/FII Holdings
    Promoters held 70.42 per cent stake in the company as of 30-Sep-2021, while FIIs owned 14.23 per cent, DIIs 4.66 per cent.



    (Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.
    The Economic Times

    Stories you might be interested in